Table 2.

Abstinence rates at follow-up

Continuous Abstinence (weeks 1–4)
Treatments
Snus (n = 51)Taboka (n = 52)NRT (n = 27)
abstinent%abstinent%abstinent%P-value
1CO Verified2243.11732.71140.70.55
CO verified point prevalence abstinence
Treatments
Snus (n = 51)Taboka (n = 52)NRT (n = 27)
Visitabstinent%abstinent%abstinent%P-value
Week 42956.92242.31555.60.3
Week 6 (1 week follow-up)2447.12038.51555.60.35
Week 16 (11 weeks follow-up)1631.41223.1933.30.54
CO and cotinine verified point prevalence abstinence
Treatments
Snus (n = 51)Taboka (n = 52)NRT (n = 27)
Visitabstinent%abstinent%abstinent%P-value
Week 6 (1 week follow-up)1427.51223.1829.60.76
Week 16 (11 weeks follow-up)1019.6713.5414.80.71